Prevalence of Amino acid mutation in hepatitis C virus core region among Japanese volunteer blood donors

Furui, Yasumi; Hoshi, Yuji; Murata, Kazumoto; Ito, Kiyoaki; Suzuki, Kou; Uchida, Shigeharu; Satake, Masahiro; Mizokami, Masashi; Tadokoro, Kenji

doi:10.1002/jmv.22216

Cited by 7 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most interesting finding of this study is that the amino acid at position 91 is different in HCV‐1b (Lue 91 Met) than HCV‐1a and HCV genotype 4 where Cys 91 is well conserved (Alhamlan et al, unpublished data). In addition, this study is in agreement with a recent study that reported Gln 70 and/or Met 91 are associated with poor response in HCV‐1b subgenotype but not in those with other genotypes [Furui et al, ]. Further investigations are needed to determine the significance of specific mutations in each genotype and how they affect the response to the treatment.…”

Section: Discussionsupporting

confidence: 91%

Hepatitis C virus genotype 1: How genetic variability of the core protein affects the response to pegylated‐interferon and ribavirin therapy

Alhamlan

Al-Ahdal

Khalaf

et al. 2013

Journal of Medical Virology

View full text Add to dashboard Cite

Hepatitis C virus subgenotypes 1a and 1b are found worldwide and cause 60% of all hepatitis C cases. It has been reported recently that viral genetic variations have a critical impact on the patient treatment outcome. In particular, polymorphisms of the HCV core protein have been linked to poor treatment response. However, most of these studies were conducted on Asian populations, Japanese in particular who are infected with HCV subgenotype 1b. Hence, we aimed in this study to examine the core protein polymorphisms in Saudi patients who are infected with chronic HCV genotype 1 (1a and 1b subtypes) and its association with treatment outcome. Direct sequencing of full-length core protein and data mining analyses were utilized. Results have shown that the response to treatment is dependent on subgenotypes. Indeed, HCV-1b showed different point mutations that are associated with treatment outcome where the point mutations at positions 70 (Arg(70) Gln) and 75 (Thr(75) Ala) in HCV-1b are significantly associated with PEG-IFN/RBV treatment response. In contrast, HCV-1a showed no significant association between core protein mutations and response to treatment. In addition, analyses of HCV-1a core protein sequences revealed a highly conserved region especially in the responder group. This study provides a new insight in the genetic variability of full-length core protein in HCV genotype 1 in Saudi infected patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Hepatitis C virus genotype 1: How genetic variability of the core protein affects the response to pegylated‐interferon and ribavirin therapy

Alhamlan

Al-Ahdal

Khalaf

et al. 2013

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…As: Asian countries like Ch: China and J: Japan (including prevalence data of Furui et al [39], for which sequences are not available); RW: Rest of the world. Numbers in bold refer to mutations found at higher frequency compared to other genotypes or locations.…”

Section: Resultsmentioning

confidence: 99%

“…Treatment with IFN/RBV has been proposed to induce these amino acid mutations [23]. Another possible explanation is that these mutations might be selected during the natural course of infection, in response to the selective pressure of endogenous IFN [39]. The relatively high frequency of these mutations in patients not treated with IFN/RBV might be associated to the transmission of HCV isolates from treated patients.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates

Jaspe

Sulbarán

et al. 2012

Virol J

View full text Add to dashboard Cite

BackgroundRecent reports show that R70Q and L/C91M amino acid substitutions in the core from different hepatitis C virus (HCV) genotypes have been associated with variable responses to interferon (IFN) and ribavirin (RBV) therapy, as well to an increase of hepatocellular carcinoma (HCC) risk, liver steatosis and insulin resistance (IR). Mutations in NS5B have also been associated to IFN, RBV, nucleoside and non-nucleoside inhibitors drug resistance. The prevalence of these mutations was studied in HCV RNA samples from chronically HCV-infected drug-naïve patients.MethodsAfter amplification of core and NS5B region by nested-PCR, 12 substitutions were analyzed in 266 Venezuelan HCV isolates subtype 1a, 1b, 2a, 2c, 2b, 2j (a subtype frequently found in Venezuela) and 3a (n = 127 and n = 228 for core and NS5B respectively), and compared to isolates from other countries (n = 355 and n = 646 for core and NS5B respectively).ResultsR70Q and L/C91M core substitutions were present exclusively in HCV G1b. Both substitutions were more frequent in American isolates compared to Asian ones (69% versus 26%, p < 0.001 and 75% versus 45%, p < 0.001 respectively). In Venezuelan isolates NS5B D310N substitution was detected mainly in G3a (100%) and G1a (13%), this later with a significantly higher prevalence than in Brazilian isolates (p = 0.03). The NS5B mutations related to IFN/RBV treatment D244N was mainly found in G3a, and Q309R was present in all genotypes, except G2. Resistance to new NS5B inhibitors (C316N) was only detected in 18% of G1b, with a significantly lower prevalence than in Asian isolates, where this polymorphism was surprisingly frequent (p < 0.001).ConclusionsGenotypical, geographical and regional differences were found in the prevalence of substitutions in HCV core and NS5B proteins. The substitutions found in the Venezuelan G2j type were similar to that found in G2a and G2c isolates. Our results suggest a high prevalence of the R70Q and L/C91M mutations of core protein for G1b and D310N substitution of NS5B protein for the G3a. C316N polymorphism related with resistance to new NS5B inhibitors was only found in G1b. Some of these mutations could be associated with a worse prognosis of the disease in HCV infected patients.

show abstract

“…Also, Furui et al (2011) identified aa 70 and aa 91 substitutions among Japanese volunteer blood donors (Furui et al 2011).…”

Section: Discussionmentioning

confidence: 97%

Bioinformatics Analysis of Domain 1 of HCV-Core Protein: Iran

Dehghani

Hashempour

Hasanshahi

et al. 2019

Int J Pept Res Ther

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a serious global health problem and a cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). Bioinformatics software has been an effective tool to study the HCV genome as well as core domains. Our research was based on employing several bioinformatics software applications to find important mutations in domain 1 of core protein in Iranian HCV infected samples from 2006 to 2017, and an investigation of general properties, B-cell and T-cell epitopes, modification sites, and structure of domain 1. Domain 1 sequences of 188 HCV samples isolated from 2006 to 2017, Iran, were retrieved from NCBI gene bank. Using several tools, all sequences were analyzed for determination of mutations, physicochemical analysis, B-cell epitopes prediction, T-cell and CTL epitopes prediction, post modification, secondary and tertiary structure prediction. Our analysis determined several mutations in some special positions (70, 90, 91, and 110) that are associated with HCC and hepatocarcinogenesis, efficacy of triple therapy and sustained virological response, and interaction between core and CCR6. Several B-cell, T-cell, and CTL epitopes were recognized. Secondary and tertiary structures were mapped fordomain1 and core proteins. Our study, as a first report, offered inclusive data about frequent mutation in HCV-core gene domain 1 in Iranian sequences that can provide helpful analysis on structure and function of domain 1 of the core gene.

show abstract

Prevalence of Amino acid mutation in hepatitis C virus core region among Japanese volunteer blood donors

Cited by 7 publications

References 16 publications

Hepatitis C virus genotype 1: How genetic variability of the core protein affects the response to pegylated‐interferon and ribavirin therapy

Hepatitis C virus genotype 1: How genetic variability of the core protein affects the response to pegylated‐interferon and ribavirin therapy

Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates

Bioinformatics Analysis of Domain 1 of HCV-Core Protein: Iran

Contact Info

Product

Resources

About